Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') today announced that members of its executive team will present and host 1x1 meetings at the upcoming investor conferences, detailed below.
Jefferies Global Healthcare Conference
Dates: June 3 – 5 2025 | New York, USA
The executive team will participate in a fireside chat scheduled on Thursday, June 5, 2025, from 7:35 to 8:05 am EDT.
Goldman Sachs 46 th Annual Global Healthcare Conference
Dates: June 9 – 11 2025 | Miami, USA
The executive team will participate in a fireside chat scheduled on Tuesday, June 10, 2025, from 4:00 to 4:35 pm EDT.
In addition, members of the executive team will participate and represent the Company during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held from May 30 to June 3, 2025 in Chicago, Illinois.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
DigitalOcean Holdings (DOCN) Stock Falls 11% Over Past Week Amid Tech Sell-Offs
DigitalOcean Holdings announced the launch of its GradientAI Platform, a major leap in simplifying AI integration for enterprises. Despite this launch, the company's stock dropped 11% over the past week. The broader market decline, provoked by weak job data and tariff-related uncertainties, may have influenced this dip. The tech-heavy Nasdaq's struggle, combined with widespread tech sell-offs, likely added weight to DigitalOcean's stock movement, rather than countering it. While the company's innovative platform aims to drive growth, its recent price movement reflects broader market trends more than the company's specific developments. You should learn about the 2 possible red flags we've spotted with DigitalOcean Holdings. We've found 22 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. DigitalOcean Holdings' recent announcement of the GradientAI Platform may significantly impact future revenue and earnings by simplifying AI integration for its enterprise clients. This aligns with their ongoing expansion in AI activities, as highlighted in their 160% year-over-year AI ARR growth, and could enhance their revenue stream. However, despite these developments, the company's shares have not shown immediate positive returns. Over the last year, DigitalOcean's total shareholder return was a 10.28% decline, reflecting broader challenges in the tech sector, particularly within the context of US$806.59 million in revenue and US$108.56 million in earnings. This underperformance is also evident when compared to both the US market and the IT industry, which saw returns of 17.5% and 22.8%, respectively, over the same period. The launch of DigitalOcean's AI initiatives indicates potential upside in revenue and earnings forecasts, partially supported by projections of a 13.2% annual revenue growth. Analyst forecasts suggest earnings could rise, fueled by strategic investments in data center expansion and increased ARPU. These forecasts support a price target of US$38.82, representing a significant potential upside from the current share price of US$25.74. However, the ambitious price target requires future performance alignment with analyst expectations, including substantial revenue and earnings improvements. Thus, while the GradientAI launch is promising, its immediate effect on share prices appears muted by larger market dynamics, leaving analysts' projections to reflect more optimistic longer-term potential. Click here to discover the nuances of DigitalOcean Holdings with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include DOCN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Skift
39 minutes ago
- Skift
Travel Deal Activity Drops 8% in First Half of 2025
The DJIA fell 542 points on Friday, while the Nasdaq was down 472, the S&P 500fell 101 points, and the 10-year treasury yield was down .14 to 4.22%. It was a rough last two days of the week in the market, meaning the earnings reports, good or bad, did not really matter. BHR reported results, and they were down -5%, the only mover of note in the group. Park Hotels and Xenia Hotels had opposite type 2Q25 reports. PK beat estimates but tightened guidance, and not in a good way. They are now expecting flat to down -2% RevPAR in 2025. PK also said they are permanently closing the Embassy Suites Kansas City Plaza in this current quarter. They did not repurchase any shares in 2Q25. XHR, on the other hand, reported a 2Q that was very much ahead of expectations but did not change their 2025 outlook, guidance raised to reflect 2Q's results, clearly deemed to be a conservative stance. They bought back $35.7 million worth of stock in the quarter, 2.8% of the shares
Business Insider
2 hours ago
- Business Insider
Trump Fires Labor Stats Chief after July Jobs Miss and Revisions Hit Market
President Donald Trump removed Bureau of Labor Statistics Commissioner (BLS) Erika McEntarfer on Friday, after the agency reported July job growth came in far below forecasts. The BLS posted an increase of 73,000 nonfarm payrolls for the month, missing expectations and triggering a sharp market reaction. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The president announced the decision on Truth Social. He claimed the commissioner, appointed in 2024 under President Joe Biden, had produced flawed data. Trump alleged the report was manipulated to harm the economy's perceived strength. However, no official evidence supports this claim. Until a replacement is confirmed, Deputy Commissioner William Wiatrowski will serve as acting head of the agency. Powell in Trump's Crosshairs In the same post, Trump criticized Federal Reserve Chair Jerome Powell. He called for Powell's removal, citing interest rate decisions that, in his view, counteracted the broader economic policy. On Wednesday, the Federal Open Market Committee voted to hold the benchmark rate steady. Markets have now priced in a strong chance of a rate cut in September. The BLS also revised May and June job totals lower by a combined 258,000. That brought the three-month average to 35,000, the weakest stretch since April 2020. Economists note revisions are standard and reflect updated data, not political bias. Markets moved lower after the release. The Dow Jones Industrial Average (DJIA) fell over 500 points. The Nasdaq dropped more than 2%. Treasury yields declined as traders adjusted rate expectations. Data Integrity in Focus Critics of the decision include William Beach, a 2017 Trump appointee and former BLS chief. He said the move threatens the agency's independence and the reliability of federal data. Multiple public sector groups have raised similar concerns. The Bureau of Labor Statistics is part of the Department of Labor and provides key reports on jobs, inflation, and productivity. Its data is used by investors, businesses, and policymakers. The White House has promoted prior reports as signs of labor strength. Following the June numbers, it called the figures a 'June Boom.' Trump has frequently highlighted payroll gains while in office. The latest report, along with the firing, raises new focus on how economic data is produced and viewed during the 2025 election cycle.
